Home › Therapeutic areas › Respiratory › Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (8 companies)
Companies with an active program in Idiopathic Pulmonary Fibrosis.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AGMB | Agomab Therapeutics | ImmunologyRespiratory Rare | 1 | Phase 2 | $376M | 4 |
| CTNM | Contineum Therapeutics | NeurologyRespiratory Rare | 1 | Phase 2 | $374M | 4 |
| INSM | Insmed | CardiovascularImmunology+3 Rare | 2 | Approved | $25.1B | 15 |
| LQDA | Liquidia | CardiovascularImmunology+1 Rare | 1 | Approved | $3.97B | 9 |
| RNTX | Rein Therapeutics | Respiratory Rare | 1 | Phase 2 | $53.0M | 1 |
| RVPH | Reviva Pharmaceuticals | CardiovascularDermatology+2 Rare | 1 | Phase 3 | $4.8M | 10 |
| SRPT | Sarepta Therapeutics | NeurologyRespiratory Rare | 1 | Approved | $1.91B | 11 |
| GPCR | Structure Therapeutics | MetabolicRespiratory Rare | 1 | Phase 3 | $4.35B | 5 |
No companies match.